AbbVie Inc
USUSDAbbVie Inc (MX:ABBV) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- abbvie.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- North Chicago, United States
- Administrerende Direktør
- Robert A. Michael
- Ansatte
- 57 000
- Grundlagt
- 2012
- Børsnoteret Siden
- 25.11.2013 (MX:ABBV)
- Udestående Aktier
- Free Float
- 1.76 mia.
- Markedsværdi
- 470.55 mia. USD
- Insidere
- 0.11%
- Institutionelle Investorer
- 77.37%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk Form
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- P/E
- 82.4
- Udbetalingsgrad
- 190%
- FCF
- 18.2 mia. USD
- Udbetaling / FCF
- 66%
- Gæld
- 70.8 mia. USD3.5 år FCF
- Udbyttestreak
- 13 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
- NAV
Beskrivelse
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Udbytte
AbbVie Inc (ABBV) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 125.1534 MXN pr. Aktie (betalinger: 4). Det svarer til cirka 2.38% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 15.01.2027. Uafbrudt udbyttehistorik: 13 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-15 | — | 31.8943 MXN | 0.6/2.4 % | kvartalsvis | MX:ABBV |
| 2026-07-15 | — | 31.0864 MXN | 0.7/2.8 % | kvartalsvis | MX:ABBV |
| 2026-04-15 | — | 31.0864 MXN | 0.9/3.4 % | kvartalsvis | MX:ABBV |
| 2026-01-16 | — | 31.0864 MXN | 0.8/3.1 % | kvartalsvis | MX:ABBV |
| 2025-10-15 | — | 29.4692 MXN | 0.7/2.8 % | kvartalsvis | MX:ABBV |
| 2025-07-15 | — | 29.4692 MXN | 0.8/3.2 % | kvartalsvis | MX:ABBV |
| 2025-04-15 | — | 29.4692 MXN | 0.8/3.2 % | kvartalsvis | MX:ABBV |
| 2025-01-15 | — | 29.4692 MXN | 0.8/3.1 % | kvartalsvis | MX:ABBV |
| 2024-10-15 | — | 27.8520 MXN | 0.7/3.0 % | kvartalsvis | MX:ABBV |
| 2024-07-15 | — | 27.8520 MXN | 0.9/3.7 % | kvartalsvis | MX:ABBV |
| 2024-04-12 | — | 27.8520 MXN | 1.0/3.9 % | kvartalsvis | MX:ABBV |
| 2024-01-12 | — | 27.8520 MXN | 1.0/3.9 % | kvartalsvis | MX:ABBV |
| 2023-10-12 | — | 26.5941 MXN | 1.0/4.0 % | kvartalsvis | MX:ABBV |
| 2023-07-13 | — | 26.5941 MXN | 1.2/4.6 % | kvartalsvis | MX:ABBV |
| 2023-04-13 | — | 26.5941 MXN | 0.9/3.5 % | kvartalsvis | MX:ABBV |
| 2023-01-12 | — | 26.5941 MXN | 0.8/3.3 % | kvartalsvis | MX:ABBV |
| 2022-10-13 | — | 25.3363 MXN | 0.9/3.6 % | kvartalsvis | MX:ABBV |
| 2022-07-14 | — | 25.3363 MXN | 0.8/2.4 % | kvartalsvis | MX:ABBV |
| 2022-04-13 | — | 25.3363 MXN | 0.8/1.5 % | kvartalsvis | MX:ABBV |
| 2022-01-13 | — | 25.3363 MXN | 0.9/0.9 % | kvartalsvis | MX:ABBV |
Nyheder Denne Uge
Pressemeddelelser fra virksomhedens investorhjemmeside, opdateret dagligt. Links fører til virksomhedens hjemmeside. Overskrifterne er på originalsproget, som på virksomhedens hjemmeside.
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 mio. | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 mio. | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 mio. | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 mio. | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 mio. | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 mio. | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 mio. | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 mio. | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 mio. | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 mio. | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
